Two great examples are Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) and Vertex Pharmaceuticals (NASDAQ: VRTX). Warren ...

Vertex Pharmaceuticals Inc. closed 14.97% short of its 52-week high of $519.88, which the company achieved on November 8th.

Cofounder John Donohue is stepping down on May 31 from his job as chief executive. He’ll still chair the company’s board and ...

UBS analyst Eliana Merle reaffirmed a Buy rating and a $582 price target for Vertex Pharmaceuticals, praising the adoption of ...

The AI agents mark a significant milestone as a direct outcome of the Google Cloud C enter of E xcellence, powered by Infosys Topaz™. The initiative leverages the advanced AI capabilities of Infosys ...

Vertex Pharmaceuticals is riding high on analyst confidence, thanks to its leadership in NAV1.8 inhibitors and smart partnerships. Jefferies analyst Michael Yee recently reaffirmed a Buy rating, ...

Vertex has built its earnings thanks to its CF program, and with a new CF drug approved a few months ago, the company may be ...

Reshma Kewalramani, Bela Bajaria, Revathi Advaithi and Meena Lakdawala Flynn among women at the top of the global business ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Palmonas specialises in demi-fine jewellery such as necklaces, rings, bracelets, earrings, and mangalsutras made from ...

Vertex Minerals Ltd. ( ($AU:VTX) ) has provided an announcement. Vertex Minerals Ltd. has announced a Share Purchase Plan (SPP) following a ...